Accéder au contenu
Merck

Human gut bacterial metabolism drives Th17 activation and colitis.

Cell host & microbe (2021-11-26)
Margaret Alexander, Qi Yan Ang, Renuka R Nayak, Annamarie E Bustion, Moriah Sandy, Bing Zhang, Vaibhav Upadhyay, Katherine S Pollard, Susan V Lynch, Peter J Turnbaugh
RÉSUMÉ

Bacterial activation of T helper 17 (Th17) cells exacerbates mouse models of autoimmunity, but how human-associated bacteria impact Th17-driven disease remains elusive. We show that human gut Actinobacterium Eggerthella lenta induces intestinal Th17 activation by lifting inhibition of the Th17 transcription factor Rorγt through cell- and antigen-independent mechanisms. E. lenta is enriched in inflammatory bowel disease (IBD) patients and worsens colitis in a Rorc-dependent manner in mice. Th17 activation varies across E. lenta strains, which is attributable to the cardiac glycoside reductase 2 (Cgr2) enzyme. Cgr2 is sufficient to induce interleukin (IL)-17a, a major Th17 cytokine. cgr2+ E. lenta deplete putative steroidal glycosides in pure culture; related compounds are negatively associated with human IBD severity. Finally, leveraging the sensitivity of Cgr2 to dietary arginine, we prevented E. lenta-induced intestinal inflammation in mice. Together, these results support a role for human gut bacterial metabolism in driving Th17-dependent autoimmunity.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Roche
DNase I, grade II, from bovine pancreas
Sigma-Aldrich
Uvaol, ≥95%